PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-36.98%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-26.05%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-129.84%
Negative EBIT growth while 6203.T is at 46.81%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-151.38%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-173.20%
Negative net income growth while 6203.T stands at 82.46%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-173.27%
Negative EPS growth while 6203.T is at 82.45%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-173.27%
Negative diluted EPS growth while 6203.T is at 82.45%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.63%
Negative OCF growth while 6203.T is at 3.60%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.63%
Negative FCF growth while 6203.T is at 3.60%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
112.34%
10Y revenue/share CAGR above 1.5x 6203.T's 2.76%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
41.54%
Positive 5Y CAGR while 6203.T is negative. John Neff might see an underappreciated edge for the firm vs. the competitor.
10.69%
3Y revenue/share CAGR at 50-75% of 6203.T's 16.77%. Martin Whitman would question if the firm lags behind competitor innovations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.41%
Negative 10Y net income/share CAGR while 6203.T is at 31.94%. Joel Greenblatt sees a major red flag in long-term profit erosion.
48.41%
Positive 5Y CAGR while 6203.T is negative. John Neff might view this as a strong mid-term relative advantage.
-9.44%
Negative 3Y CAGR while 6203.T is 5246.35%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
119.65%
10Y equity/share CAGR above 1.5x 6203.T's 31.66%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
36.70%
5Y equity/share CAGR 1.25-1.5x 6203.T's 24.85%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
25.80%
3Y equity/share CAGR 1.25-1.5x 6203.T's 21.88%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.79%
Firm’s AR is declining while 6203.T shows 19.50%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
13.43%
Inventory growth well above 6203.T's 11.12%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.95%
Negative asset growth while 6203.T invests at 4.50%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
3.07%
BV/share growth above 1.5x 6203.T's 1.55%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-4.40%
We’re deleveraging while 6203.T stands at 10.06%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-18.67%
Our R&D shrinks while 6203.T invests at 3.90%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
19.64%
SG&A growth well above 6203.T's 9.93%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.